Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: orlistat

« Back to Dashboard

Summary for Generic Name: orlistat

Tradenames:2
Patents:2
Applicants:2
NDAs:2
Drug Master File Entries: see list9
Suppliers: see list3

Pharmacology for Ingredient: orlistat

Clinical Trials for: orlistat

Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
Status: Completed Condition: Obesity

Study of Fat Malabsorption by Lipiblock Versus Xenical
Status: Completed Condition: Obesity

Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
Status: Completed Condition: Overweight

Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
Status: Completed Condition: Overweight; Eating Disorders

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Status: Not yet recruiting Condition: Type 1 Hyperlipoproteinemia

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
Status: Completed Condition: Obesity

The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects
Status: Withdrawn Condition: Overweight

A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
Status: Completed Condition: Overweight

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
Status: Completed Condition: Diabetes Mellitus; Obesity

Risk Management Plan (RMP) Survey for Purchasers of AlliĀ® (60 mg Orlistat) in the European Union.
Status: Not yet recruiting Condition: Obesity; Overweight

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
XENICAL
orlistat
CAPSULE;ORAL020766Apr 23, 1999RXYes6,004,996*PED<disabled>Y<disabled>
Glaxosmithkline Cons
ALLI
orlistat
CAPSULE;ORAL021887Feb 7, 2007OTCYes6,004,996<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc